Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Cancer Treat Rev. 2015 Mar 27;41(5):391–400. doi: 10.1016/j.ctrv.2015.03.008

Figure 2.

Figure 2

Indirect targeting of EWS-FLI1. A) Interaction between EWS-FLI1 and PARP. PARP inhibitors are used to directly target EWS-FLI1. B) EWS-FLI1 regulates gene expression by binding to RHA, a transcription modulator. YK-4-279, interrupts of the binding of RHA to EWS-FLI1. C) EWS-FLI1 regulates transcription of aurora kinase A, which is a cell cycle regulator. Aurora kinase inhibitors are being used to indirectly target EWS-FLI1.